Statin therapy for prevention of vascular events should be offered to lower-risk subjects
This article has no abstract so we have provided the first paragraph of the full text.
The heart protection study—a randomized, placebo-controlled trial of 20,536 men and women in the UK aged 40–80 years and at increased risk of vascular events—demonstrated the effectiveness of simvastatin (40 mg per day for 5 years) in reducing the rates of major vascular events. The authors have now used these data to predict whether lifetime use of the drug is cost-effective in a range of different age and risk groups.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
DisSARMing Toll-like receptor signalingNature Immunology News and Views (01 Oct 2006)
Chemical biology Dressed-up proteinsNature News and Views (26 Apr 2007)
